A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

Catriona M Turnbull, Paolo Marcarino, Tara A Sheldrake, Loretta Lazzarato, Clara Cena, Roberta Fruttero, Alberto Gasco, Sarah Fox, Ian L Megson, Adriano G Rossi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing group have potent anti-platelet effects, here we investigate their anti-inflammatory properties. Here we examine their effects upon TNFalpha release from lipopolysaccharide (LPS)-stimulated human monocytes and monocyte-derived macrophages and investigate a potential mechanism of action through effects on LPS-stimulated nuclear factor-kappa B (NF-kappaB) activation.
Original languageEnglish
Pages (from-to)12
JournalJournal of Inflammation (London, England)
Volume5
DOIs
Publication statusPublished - 2008

Fingerprint Dive into the research topics of 'A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages'. Together they form a unique fingerprint.

  • Cite this